CareDx (NASDAQ: CDNA) is one of 21 public companies in the “Medical laboratories” industry, but how does it contrast to its rivals? We will compare CareDx to similar businesses based on the strength of its dividends, earnings, analyst recommendations, institutional ownership, risk, profitability and valuation.
Earnings & Valuation
This table compares CareDx and its rivals revenue, earnings per share and valuation.
CareDx’s rivals have higher revenue and earnings than CareDx. CareDx is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This table compares CareDx and its rivals’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
This is a summary of recent ratings and price targets for CareDx and its rivals, as reported by MarketBeat.
||Strong Buy Ratings
CareDx currently has a consensus target price of $8.88, indicating a potential upside of 0.51%. As a group, “Medical laboratories” companies have a potential upside of 16.87%. Given CareDx’s rivals higher probable upside, analysts clearly believe CareDx has less favorable growth aspects than its rivals.
Insider and Institutional Ownership
51.5% of CareDx shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Medical laboratories” companies are owned by institutional investors. 5.4% of CareDx shares are owned by company insiders. Comparatively, 18.5% of shares of all “Medical laboratories” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Risk & Volatility
CareDx has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500. Comparatively, CareDx’s rivals have a beta of 1.23, suggesting that their average stock price is 23% more volatile than the S&P 500.
CareDx rivals beat CareDx on 7 of the 12 factors compared.
CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. Its products under development for transplant monitoring include AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. It offers the AlloMap Score Variability service, which provides complementary information to help personalize long-term care of heart transplant recipients.
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.